Azimut Exploration Inc. press release

Today's Research Reports on TSO3, Emerald Health Therapeutics, Emblem and BELLUS Health

2018-11-16

TSXV - TSX Venture Exchange · Gold · Silver · Copper · Zinc · Antimony · Lithium · Cesium · Rubidium · Gallium · Tin · Nickel · Platinum · Palladium · Platinum Group Metals · Cobalt · Molybdenum · Rare Earth Elements · Tungsten · Canada

NEW YORK, NY / ACCESSWIRE / November 16, 2018 /MarketEdge Report strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://marketedgereport.comand get exclusive access to our numerous research reports and market updates.

MER Initiates Coverage on:

TSO3 Inc. https://marketedgereport.com/report/TOS.TO/

Emerald Health Therapeutics, Inc. https://marketedgereport.com/report/EMH.V/

Emblem Corp. https://marketedgereport.com/report/EMC.V/

BELLUS Health Inc. https://marketedgereport.com/report/BLU.TO/

TSO3’s stock moved 2.17% lower Thursday, to close the day at $0.45. The stock recorded a trading volume of 40,900 shares, which was below its three months average volume of 125,790 shares. In the last year, TSO3's shares have traded in a range of 0.39 - 2.83. The share price has gained 15.38% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.51 is lower than its 200-day moving average of $0.73. Shares of TSO3 have fallen approximately 82.76 percent year-to-date.

Access MER's TSO3 Inc. Research Report at: https://marketedgereport.com/report/TOS.TO/

On Thursday, shares of Emerald Health Therapeutics recorded a trading volume of 519,147 shares, which was below the three months average volume of 1,420,181 shares. The stock ended the day 4.79% higher at $4.16. The share price has fallen 57.02% from its 52 weekhigh with a 52 weektrading range of 2.10 - 9.68. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $4.38 is greater than its 200-day moving average of $4.07. Shares of Emerald Health Therapeutics have fallen approximately 20.15 percent year-to-date.

Access MER's Emerald Health Therapeutics, Inc. Research Report at: https://marketedgereport.com/report/EMH.V/

Emblem Health’s stock jumped 8.4% Thursday, to close the day at $1.29. The stock recorded a trading volume of 593,645 shares, which was below its three months average volume of 805,909 shares. In the last year, Emblem Health's shares have traded in a range of 1.08 - 2.76. The share price has gained 19.44% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $1.62 is greater than its 200-day moving average of $1.44. Shares of Emblem Health have fallen approximately 43.42 percent year-to-date.

Access MER's Emblem Corp. Research Report at: https://marketedgereport.com/report/EMC.V/

On Thursday, shares of BELLUS Health recorded a trading volume of 66,447 shares, which was below the three months average volume of 381,246 shares. The stock ended the day flat at $0.92. The share price has fallen 23.33% from its 52 weekhigh with a 52 weektrading range of 0.33 - 1.20. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.95 is greater than its 200-day moving average of $0.74. Shares of BELLUS Health have gained approximately 148.65 percent year-to-date.

Access MER's BELLUS Health Inc. Research Report at: https://marketedgereport.com/report/BLU.TO/

Our Actionable Research on TSO3 Inc. (TSX :TOS.TO), Emerald Health Therapeutics, Inc. (TSXV :EMH.V), Emblem Corp. (TSXV :EMC.V) and BELLUS Health Inc. (TSX :BLU.TO) can be downloaded free of charge at MarketEdge Report.

MarketEdge Report

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

MarketEdge has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of MarketEdgeReport.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. MarketEdgeReport.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.marketedgereport.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

MarketEdge Report, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@marketedgereport.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: MarketEdgeReport